Medlab Clinical


Market CapAU$51.3m

Last Close AU$0.15

More Medlab Clinical content >

Investment summary

Medlab is a drug delivery biotechnology company with a proprietary platform, NanoCelle, which is a patented nanomicellar formulation that can improve the delivery of drugs. With the growing appreciation of the medicinal properties of cannabis, Medlab’s lead product became NanaBis, a THC:CBD (1:1) cannabis extract encapsulated in NanoCelle particles, which enable a convenient buccal spray delivery. The most recent breakthrough was Medlab’s announcement that it had successfully produced a synthetic version of NanaBis, thus significantly streamlining the regulatory pathway. Once the product reformulation is done (current guidance is eight to 10 months), NanaBis will re-enter clinical development (potentially Phase III) as a fully synthetic, non-opioid pain relief drug optimised with proprietary delivery technology aimed at a vast market.

Content on Medlab Clinical
View more
Share price graph
Price performance
Actual (25.0) (42.3) (3.2)
Relative* (27.2) (46.4) (21.6)
52-week high/low A$0.4/A$0.1
*% relative to local index
Key management
Sean Hall CEO